Surrogate endpoints.
作者信息
Ellenberg S S
出版信息
Br J Cancer. 1993 Sep;68(3):457-9. doi: 10.1038/bjc.1993.369.
Abstract
摘要
相似文献
1
Surrogate endpoints.替代终点
Br J Cancer. 1993 Sep;68(3):457-9. doi: 10.1038/bjc.1993.369.
2
The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.临床试验中替代终点的应用：聚焦于心血管疾病的临床试验。
Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):497-508. doi: 10.1002/pds.654.
3
Endpoints in cancer clinical trials.癌症临床试验终点。
J Visc Surg. 2014 Feb;151(1):17-22. doi: 10.1016/j.jviscsurg.2013.10.001. Epub 2014 Jan 14.
4
Can the long road from bench to bedside be shortened?
J Natl Cancer Inst. 2001 May 16;93(10):738-40. doi: 10.1093/jnci/93.10.738.
5
Surrogate End Points and Their Validation in Oncology Clinical Trials.替代终点及其在肿瘤学临床试验中的验证
J Clin Oncol. 2016 May 1;34(13):1436-7. doi: 10.1200/JCO.2016.66.4581. Epub 2016 Mar 7.
6
Potential surrogate endpoints in cancer research--some considerations and examples.癌症研究中的潜在替代终点——一些思考与实例
Pharm Stat. 2011 Jan-Feb;10(1):34-9. doi: 10.1002/pst.406.
7
Biomarkers as surrogate endpoints in cancer trials.生物标志物作为癌症试验中的替代终点。
Semin Oncol Nurs. 2012 May;28(2):99-108. doi: 10.1016/j.soncn.2012.03.006.
8
Statistical considerations for the next generation of clinical trials.下一代临床试验的统计学考虑。
Semin Oncol. 2011 Aug;38(4):598-604. doi: 10.1053/j.seminoncol.2011.05.014.
9
Biological markers: Tailoring treatment and trials to prognosis.生物标志物：根据预后调整治疗与试验
Nat Rev Clin Oncol. 2013 Aug;10(8):429-30. doi: 10.1038/nrclinonc.2013.97. Epub 2013 Jun 11.
10
Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.替代终点验证过程中的决策是否会随治疗效果的显著性水平而改变？关于替代终点验证的一项提议。
Contemp Clin Trials. 2009 Jan;30(1):8-12. doi: 10.1016/j.cct.2008.08.006. Epub 2008 Sep 9.
引用本文的文献
1
Surrogate endpoint metaregression: useful statistics for regulators and trialists.替代终点荟萃回归：监管者和研究者的有用统计学方法。
J Clin Epidemiol. 2024 Nov;175:111508. doi: 10.1016/j.jclinepi.2024.111508. Epub 2024 Aug 31.
2
Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer Screening.评估4种生物标志物的简单方法：替代终点、预后、预测和癌症筛查。
Biomark Insights. 2020 Aug 4;15:1177271920946715. doi: 10.1177/1177271920946715. eCollection 2020.
3
An investigator's introduction to statistical considerations in clinical trials.临床试验中统计考虑因素的研究者入门
Urol Oncol. 2019 May;37(5):305-312. doi: 10.1016/j.urolonc.2018.12.025. Epub 2019 Mar 26.
4
Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD.低风险 AMD 患者接受阈下二极管微脉冲激光（SDM）治疗后脉络膜新生血管（CNV）发生率低。
PLoS One. 2018 Aug 23;13(8):e0202097. doi: 10.1371/journal.pone.0202097. eCollection 2018.
5
Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials.基于多个先前试验数据，使用替代终点预测治疗效果的 5 项标准。
Stat Med. 2018 Feb 20;37(4):507-518. doi: 10.1002/sim.7561. Epub 2017 Nov 21.
6
Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action.丙型肝炎临床试验风险：终点选择与药物作用。
Can J Gastroenterol Hepatol. 2016;2016:6260271. doi: 10.1155/2016/6260271. Epub 2016 Mar 30.
7
University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (morning panel discussion).宾夕法尼亚大学第七届临床试验统计问题年度会议：临床试验中生物标志物和替代终点使用的当前问题（上午小组讨论）
Clin Trials. 2015 Aug;12(4):323-32. doi: 10.1177/1740774515590090. Epub 2015 Jun 10.
8
Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes.评估替代终点、预后标志物和预测标志物：一些简单的主题。
Clin Trials. 2015 Aug;12(4):299-308. doi: 10.1177/1740774514557725. Epub 2014 Nov 10.
9
Surrogate endpoints in liver surgery related trials: a systematic review of the literature.肝外科相关临床试验中的替代终点：文献系统综述。
HPB (Oxford). 2013 May;15(5):327-36. doi: 10.1111/j.1477-2574.2012.00590.x. Epub 2012 Oct 22.
10
Surrogate endpoint analysis: an exercise in extrapolation.替代终点分析：外推法的实践。
J Natl Cancer Inst. 2013 Mar 6;105(5):316-20. doi: 10.1093/jnci/djs527. Epub 2012 Dec 21.
本文引用的文献
1
Preliminary analysis of the Concorde trial. Concorde Coordinating Committee.协和试验的初步分析。协和协调委员会。
Lancet. 1993 Apr 3;341(8849):889-90. doi: 10.1016/0140-6736(93)93096-j.
2
CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.对于正在服用齐多夫定的无症状HIV感染者，CD4 + 淋巴细胞是临床进展的不完整替代标志物。
Ann Intern Med. 1993 May 1;118(9):674-80. doi: 10.7326/0003-4819-118-9-199305010-00003.
3
Studies in variation associated with the measurement of solid tumors.与实体瘤测量相关的变异研究。
Cancer. 1980 Sep 1;46(5):1286-90. doi: 10.1002/1097-0142(19800901)46:5<1286::aid-cncr2820460533>3.0.co;2-f.
4
Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup.
Cancer Treat Rep. 1982 Apr;66(4):1023-33.
5
Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU).司莫司汀（甲环亚硝脲）辅助治疗胃肠道癌后的白血病和白血病前期
N Engl J Med. 1983 Nov 3;309(18):1079-84. doi: 10.1056/NEJM198311033091802.
6
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.测量误差对评估抗癌化疗反应的影响：肿瘤反应新标准的提议
J Clin Oncol. 1984 Sep;2(9):1040-6. doi: 10.1200/JCO.1984.2.9.1040.
7
Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate.
Cancer. 1973 Nov;32(5):1126-30. doi: 10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c.
8
Surrogate endpoints in clinical trials: cancer.临床试验中的替代终点：癌症。
Stat Med. 1989 Apr;8(4):405-13. doi: 10.1002/sim.4780080404.
9
CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use.
J Acquir Immune Defic Syndr (1988). 1989;2(2):114-24.
10
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.前列腺特异性抗原作为前列腺腺癌的血清标志物。
N Engl J Med. 1987 Oct 8;317(15):909-16. doi: 10.1056/NEJM198710083171501.
Zotero 插件